Reduced functional residual capacity and severe head injury.

treatable with standard mycobacterial chemotherapy), and groups 2a and 2b (difficult to treat with usual mycobacterial therapy). Functionally, this seems to be a practical way for clinicians who do not frequently encounter these many microbes to keep track of the clinical importance of isolates. However, I am concerned about the predictable overlap of the old classification system of Runyon with this new system. Specifically, I am worried about the confusion that predictably will develop between the older designations of groups IIV (Runyon) with the new groups 0-2 (Bailey). Therefore, to reduce the potential for confusion in communication, I would suggest that the newer system advocated by Bailey be grouped only by the functional, descriptive designations: Mycobacterium: nonpathogenic, Mycobacterium: easy to treat, and Mycobacterium: difficult to treat. Underlying this proposal is the notion that for most clinicians who do not regularly encounter such microbes, this series of designations willfunction to direct their diagnostic and therapeutic considerations to more detailed literature which will indicate the specifics of management in each instance.